# A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Source: https://onco.cc/trials/nct06066203/  
OnCo record `nct06066203` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GNC-035 in non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies is a phase 1/2 interventional study registered as NCT06066203 by Sichuan Baili Pharmaceutical Co., Ltd., with 40 participants planned, started 2023-11-01 and due to reach its primary completion in 2026-12. Interventions recorded: GNC-035.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06066203
- Phase: 1/2
- Setting: An Open, Multicenter, Phase I / II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics / Pharmacodynamics and Antitumor Activity of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06066203: https://clinicaltrials.gov/study/NCT06066203

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06066203.json